Welcome to our dedicated page for Owens & Minor SEC filings (Ticker: OMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings associated with Owens & Minor, Inc. (historically NYSE: OMI) provide detailed documentation of the company’s transformation into Accendra Health, Inc. and its strategic focus on home-based care. Forms 8-K describe key events such as the entry into and completion of the Equity Purchase Agreement for the sale of the Products & Healthcare Services (P&HS) segment, the structure of the consideration received, and the company’s retained equity interest in the divested business. These filings also outline related credit facility amendments, receivables sale programs, and the release of certain subsidiaries from guarantees under term loan and note indentures.
Investors can use this filings page to access current and historical 8-K reports that explain material events, including transaction terms, transition services arrangements, and changes to executive compensation and retirement plans. The filings also document the name change from Owens & Minor, Inc. to Accendra Health, Inc. through Articles of Amendment and amended bylaws, and they state that the company expects its common stock to begin trading on the New York Stock Exchange under the ticker symbol ACH. These disclosures clarify how the legacy OMI symbol relates to the continuing entity.
Quarterly and annual reports (Forms 10-Q and 10-K, when accessed through EDGAR) provide more comprehensive information about the company’s segments, including the classification of the P&HS segment as discontinued operations and the description of continuing operations as primarily representing the Patient Direct segment and certain functional operations. They also include discussions of risk factors, capital structure, and accounting treatment of receivables sale arrangements.
On Stock Titan’s SEC filings page, users can review these documents as they are made available from EDGAR and take advantage of AI-powered tools that summarize complex disclosures. These tools can help highlight the implications of major transactions, the impact of the P&HS divestiture on the company’s financial statements, and the significance of the corporate name and ticker change for holders of the legacy OMI shares.
Accendra Health, Inc. is asking shareholders to vote at its virtual 2026 Annual Meeting on six director nominees, auditor ratification, a say-on-pay advisory vote, and approval of an amended 2023 Omnibus Incentive Plan. The record date is March 18, 2026, and the meeting will be held online on May 14, 2026.
The company highlights its strategic shift after selling its Products & Healthcare Services business on December 31, 2025, becoming a more focused, pure-play home-based care provider through its Apria and Byram Healthcare brands. For 2025, Accendra generated total revenue of $10.672 billion, total adjusted operating income of $215 million, adjusted EBITDA of $424 million, and total adjusted net income per share of $0.61, using non-GAAP measures reconciled in Appendix B.
Proxy materials emphasize corporate governance practices such as a majority voting standard for uncontested director elections, proxy access, independent board leadership, and board-level oversight of risk, ESG, and cybersecurity. Executive pay is heavily performance-based, with the CEO’s 2025 target compensation 90% variable, including annual incentives tied to adjusted EBITDA, revenue, and net debt reduction, and long-term incentives split between performance share units and restricted stock units.
Accendra Health, Inc. Schedule 13G: Kevin M. Webb reports beneficial ownership of 4,287,431 shares of Common Stock, representing 5.61% of the class as of 03/12/2026. The filing states Mr. Webb has sole voting power and sole dispositive power over all 4,287,431 shares.
The submission lists the issuer address as 10900 Nuckols Road, Suite 400, Glen Allen, Virginia, and is signed by Kevin M. Webb on 03/30/2026.
Accendra Health Inc amendment to a Schedule 13G/A states that The Vanguard Group reports 0 shares beneficially owned of Accendra Health Inc common stock as of the filing. The amendment notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report beneficial ownership separately. The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/26/2026.
Accendra Health President & CEO Edward A. Pesicka reported a tax-related share disposition, not an open-market stock sale. On the Form 4, 58,945 shares of common stock were surrendered at $2.03 per share to cover tax withholding tied to vesting of restricted stock.
These shares were delivered back to the company rather than sold to outside investors. After this transaction, Pesicka directly holds 1,090,477 shares of Accendra Health common stock, indicating he retains a substantial equity position in the company.
ACCENDRA HEALTH INC/VA/ executive reports routine tax withholding share disposition. EVP & CFO Jonathan A. Leon surrendered 11,286 shares of common stock on 2026-03-20 to the company to cover tax withholding tied to vesting of restricted stock. This was not an open-market sale. After the transaction, he directly holds 292,303 shares of common stock.
Accendra Health executive Perry A. Bernocchi reported a routine tax-related share disposition. On March 20, 2026, he surrendered 20,841 shares of common stock at $2.03 per share to the company to satisfy tax withholding obligations tied to vesting restricted stock. This was not an open-market sale, and he still directly holds 321,821 shares after the transaction.
Accendra Health executive Heath H. Galloway transferred 9,347 shares of common stock to the company at $2.03 per share to cover tax withholding on vested restricted stock. This non‑market, tax-withholding disposition leaves him holding 169,094 shares directly, reflecting a routine compensation-related adjustment rather than an open-market trade.
Galloway Heath H reported acquisition or exercise transactions in this Form 4 filing.
ACCENDRA HEALTH INC/VA/ granted EVP, General Counsel & Corporate Secretary Heath H. Galloway 61,437 shares of Common Stock as a restricted stock award. The grant carries no purchase price and vests one-third per year over three years. Following this compensation award, Galloway directly holds 178,441 Common Stock shares. This is a non-market, equity-based compensation grant rather than an open-market purchase or sale, so it reflects long-term incentive alignment more than a trading view on the stock.
Accendra Health, Inc. outlines a major reshaping of its business and key risks. The company completed the sale of its Products & Healthcare Services business for $375 million in cash, retaining a 5% equity interest, which leaves it as a smaller, single-segment home healthcare provider.
Management highlights heavy reliance on a few commercial and government payors. One large commercial payor is terminating contracts that represented $322 million, or 12% of 2025 net revenue, including nearly all capitation revenue, creating meaningful earnings and liquidity risk if not replaced or offset.
The filing stresses competitive pressures, supplier concentration, cybersecurity threats, inflation, and reimbursement uncertainty from Medicare, Medicaid and private payors. It also discusses extensive regulatory exposure, including privacy, fraud and abuse, environmental and antitrust rules, and notes Apria’s prior False Claims Act settlement and ongoing Corporate Integrity Agreement obligations through 2026.
Accendra Health, Inc. reported fourth-quarter and full-year 2025 results that reflect its shift to a standalone home-based care business after completing the sale of its Products & Healthcare Services business on December 31, 2025.
From continuing operations, net revenue rose to $708.967 million in Q4 2025 from $695.023 million a year earlier, with Q4 operating income improving to $20.9 million from a loss of $272.7 million. For 2025, continuing net revenue grew to $2.762 billion from $2.680 billion, and adjusted EBITDA was $374.847 million versus $370.515 million in 2024.
Despite better underlying performance, the company recorded a substantial full-year net loss of $1.1006 billion, driven largely by a $997.960 million loss from discontinued operations and an $80 million transaction breakage fee related to a terminated acquisition. Cash and cash equivalents increased markedly to $281.989 million at December 31, 2025, and net debt declined to $1.768 billion, while total equity moved to a deficit position. Management highlighted strong cash flow, ongoing cost controls and balance sheet optimization as it completes separation from Owens & Minor and focuses on sustainable growth.